Upregulation of ROR2 in osteosarcoma, melanoma, renal cell carcinoma, chemoresistant ovarian cancer and the relationship with higher risk diseases defined it as a tumor promoter in early studies [11, 13, 34, 35]. This evidence concerns the gene ROR2 and osteosarcoma.